Cite this article: Bone Joint J 2023;105-B(6):590–592.

The limitations and benefits of patient-reported outcome measures, in defining the merits of arthroplasty surgery, are discussed. Cite this article: Bone Joint J 2015;97-B:578–81

Due to economic constraints, it has been suggested that joint replacement patients can be followed up in primary care. There are clinical, ethical and academic reasons why we must ensure that our joint replacements are appropriately clinically and radiologically followed up to minimise complications. This Editorial discusses this

Cite this article: Bone Joint J 2023;105-B(11):1133–1134.

Cite this article: Bone Jt Open 2024;5(12):1120–1122.

The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods. Cite this article: Bone Joint Res 2021;10(2):134–136

Cite this article: Bone Joint Res 2023;12(1):5–8.

Cite this article: Bone Joint Res 2023;12(5):306–308.

Cite this article: Bone Joint Res 2023;12(10):654–656.

Cite this article: Bone Joint J 2024;106-B(1):6–8.

Cite this article: Bone Joint Res 2023;12(4):256–258.